ipo
Stage
2014
Founded
1
Investors
About
Spero Therapeutics develops differentiated medicines for patients with rare diseases and multidrug-resistant bacterial infections. The company is developing an investigational oral carbapenem (tebipenem HBr) for complicated urinary tract infections and works with external partners (e.g., GSK).
Explore Spero Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.